{"entity":{"id":"nct05044897","kind":"trial","name":"A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC","aka":[],"tldr":"A phase 2 trial of SI-B001 in head and neck squamous cell carcinoma, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.","summary":"A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC is a phase 2 interventional study registered as NCT05044897 by Sichuan Baili Pharmaceutical Co., Ltd., with 11 participants enrolled, started 2021-10-20 and due to reach its primary completion in 2025-12. Interventions recorded: SI-B001. Conditions listed: Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05044897","url":"https://clinicaltrials.gov/study/NCT05044897"}],"tags":["ctgov-ingest"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":["si-b001"],"companies":["systimmune"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05044897","phase":"2","setting":"A Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","enrolled":11,"outcomes":[]},"route":"/trials/nct05044897/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}],"drug":[{"id":"si-b001","kind":"drug","name":"SI-B001","route":"/drugs/si-b001/"}],"company":[{"id":"systimmune","kind":"company","name":"SystImmune / Sichuan Biokin","route":"/companies/systimmune/"}]}}